Cited by 191SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273

Open access

Teo, Shyh Poh·2022·Journal of Pharmacy Practice

DOI 10.1177/08971900211009650

Open this paper in CoChat — free account Open PDF

Abstract

The United States Food and Drug Administration recently issued emergency use authorization for 2 mRNA vaccines for preventing COVID-19 disease caused by SARS-CoV-2 virus infections. BNT162b2 from Pfizer-BioNTech and mRNA-1273 by Moderna are planned for use in mass-immunization programs to curb the pandemic. A brief overview of COVID-19 mRNA vaccines is provided, describing the SARS-CoV-2 RNA, how mRNA vaccines work and the advantages of mRNA over other vaccine platforms. The Pfizer-BioNTech collaboration journey to short-list mRNA vaccine candidates and finally selecting BNT162b2 based on safety data is outlined, followed by the Phase 3 study of BNT162b2 demonstrating 95% efficacy in preventing COVID-19 infections. Studies regarding mRNA-1273 (Moderna) are described, including extended immunogenicity data up to 119 days. The Phase 3 COVE study of mRNA-1273 eventually showed vaccine efficacy of 94.5%. Recommendations for future mRNA vaccine development are provided, including ongoing safety surveillance, evaluation in under-represented groups in previous studies and improving mRNA vaccine thermostability. Finally, further logistical considerations are required for manufacturing, storing, distribution and implementing mass vaccination programs to curb the pandemic.

Integrity signals

Registry

Crossref · 10.1177/08971900211009650

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Although the duration of protection from a singledose remains uncertain, a second dose does not appear to confer much additional benefit for the vaccine recipients.(29) In the Moderna trial, 81 (0.”
Background
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 1×
“During the phase 1, dose-escalation trial, 45 healthy adults aged 18 to 55 years were administered 2 doses of 25 mg, 100 mg or 250 mg of mRNA-1273 28 days apart.(18) In this study, there was a dose-dependent antibody response; with increasing titers and serum-neutralizing activity after the second vaccination at the u…”
Method
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 7

Corman VM, 2020, Eur Secur, 25, 2000045
Wang F, 2020, Med Sci Monit, 26, e924700
Vogel AB, 2020, bioRxiv, 12, 421008
10.1038/s41586-020-2639-4 · DOI · Paper page
Sahin U, 2020, medRxiv, 12, 20245175
10.1056/NEJMoa2027906 · DOI · Paper page
Skowronski DM, 2021, N Eng J Med, 384, 10

Sorted by citations

Items 101–191 of 191

Vitamin D: A Nutraceutical Supplement at the Crossroad Between Respiratory Infections and COVID-19
Rizzi, M., & Sainaghi, P. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062550 · Cited by 5
Needle-Free Jet-Delivered mRNA-Vaccine Encoding Influenza A(H1N1)pdm09 Hemagglutinin Protects Mice from Lethal Virus Infection
Sharabrin, S. V., Ilyichev, A. A., Kisakov, D. N., Borgoyakova, M. B., Starostina, E. V., Kisakova, L. A., Исаева, А. А., Щербаков, Д. Н., Krasnikova, S. I., Gudymo, A. S., et al. (2025) · Molecular Biology · doi:10.1134/s0026893325700062 · Cited by 5
The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMIRNATY vaccine (Pfizer/BioNTech)
Andries, J., Viranaïcken, W., Cordonin, C., Herrscher, C., Planesse, C., Roquebert, B., Lagrange-Xélot, M., Kalamouni, C. E., Meilhac, O., Mavingui, P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10057-7 · Cited by 5
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults
Sun, T., Li, L., Mues, K. E., Georgieva, M. V., Kirk, B., Mansi, J. A., de Velde, N. V., & Beck, E. C. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01005-1 · Cited by 6
Changing Dynamics of SARS-CoV-2: A Global Challenge
Chugh, A., Khurana, N., Verma, K., Sehgal, I., Rolta, R., Vats, P., Phartyal, R., Salaria, D., Kaushik, N., Choi, E. H., et al. (2022) · Applied Sciences · doi:10.3390/app12115546 · Cited by 5
Neutralizing Antibody Levels and Epidemiological Characteristics of Patients with Breakthrough COVID-19 Infection in Toyama, Japan
Tani, H., Inasaki, N., Shimada, T., Saga, Y., Kaya, H., Maruyama, Y., Matano, S., Itoh, H., Kashii, T., Yamazaki, E., et al. (2023) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2023.100 · Cited by 5
Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?
Cagigi, A., Tinnirello, R., Iannolo, G., & Douradinha, B. G. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107367 · Cited by 5
A Novel Trivalent BVDV mRNA Vaccine Displayed by Virus-like Particles Eliciting Potent and Broad-Spectrum Antibody Responses
Xu, S., Li, J., Xu, M., Cai, Y., Qian, Y., Liu, R., He, Q., Fei, C., Wang, A., Ruan, K., et al. (2025) · Vaccines · doi:10.3390/vaccines13070691 · Cited by 4
mRNA-Based Cancer Vaccines: A Review of the Current Scenario and Future Prospects
Bhattacharya, S., Easmin, N., Panja, A., Nayak, A., & Sur, D. (2026) · Protein and Peptide Letters · doi:10.2174/0109298665402963251022054441 · Cited by 6
mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contexts
Moschioni, M., Siraji, R. A., Dissard, R., Segafredo, G., Mutungi, H., Jain, A., Thakur, R., Maurya, N., & James, I. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2628424 · Cited by 5
Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals
Min, S. E., Gu, E.-Y., Jang, M. S., Lee, Y.-J., Han, J., Lee, W. G., Jeong, S. I., Song, J. Y., Lee, I., Kwon, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-07661-8 · Cited by 5
Live attenuated COVID-19 vaccines: approaches to development and prospects for clinical use
Korchevaya, E. R., Gracheva, A. V., Dyakov, I. N., Зверев, В. В., & Файзулоев, Е. Б. (2023) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-404 · Cited by 5
Development and application of an uncapped mRNA platform
Zheng, X., Liu, B., Ni, P., Cai, L., Shi, X., Ke, Z., Zhang, S., Hu, B., Yang, B., Xu, Y., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2437046 · Cited by 5
COVID-19 Infection and Response to Vaccination in Chronic Kidney Disease and Renal Transplantation: A Brief Presentation
Stai, S., Λιούλιος, Γ., Christodoulou, M., Kasimatis, E., Fylaktou, A., & Stangou, M. J. (2022) · Life · doi:10.3390/life12091358 · Cited by 4
Immunisation with Coronavirus-2 vaccines induces potent antibody responses and does not aggravate the lymphocyte compartment of primary Sjögren's syndrome patients
Steinmetz, T. D., de Wolff, L., Terpstra, J. H., Visser, A., Bootsma, H., Kroese, F. G. M., & Verstappen, G. M. P. J. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/1iaqnu · Cited by 4
Immunomodulation of behavior impairment via spleen-specific targeting lipid nanoparticles in a MeCP2 transgenic mouse model
Zhang, S., Li, Y., Yang, B., Teymur, A. A., Atrooz, F., Majd, S., Mohan, C., Salim, S., & Wu, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-21877-8 · Cited by 3
A Naked Lyophilized mRNA Vaccine Against Seasonal Influenza, Administered by Jet Injection, Provides a Robust Response in Immunized Mice
Sharabrin, S. V., Krasnikova, S. I., Kisakov, D. N., Borgoyakova, M. B., Yakovlev, V. A., Tigeeva, E. V., Starostina, E. V., Litvinova, V. R., Kisakova, L. A., Vahitov, D. I., et al. (2026) · Vaccines · doi:10.3390/vaccines14010056 · Cited by 3
Nucleic Acid Drugs in Radiotherapy
Yang, Y., Cai, Y., Deng, K., Xiao, Y., Liu, X., & Du, Z. H. (2025) · ChemBioChem · doi:10.1002/cbic.202400854 · Cited by 3
A Critical Assessment of COVID-19 Genomic Vaccines
Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4
Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
Agbarya, A., Sarel, I., Ziv‐Baran, T., Schwartz, O., Sheikh‐Ahmad, M., Saiegh, L., Swaid, F., Shechtman, Y., Kozlener, E., Khoury, R., et al. (2023) · Diseases · doi:10.3390/diseases11040128 · Cited by 2
Sequence confirmation of synthetic DNA exceeding 100 nucleotides using restriction enzyme mediated digestion combined with high-resolution tandem mass spectrometry
Sattler, C., Ceylan, B., Hoffmann, L., Juric, A., Kraus, J., Marandi, S., Shahnazari, A., & Rühl, M. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116180 · Cited by 3
“An Intrinsic Program Determines Key Age-Associated Changes in Adaptive Immunity That Limit Response to Non-Pathogens”
Swain, S. L., Kugler‐Umana, O., & Tonkonogy, S. L. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.701900 · Cited by 3
Ipsilateral Axillary Adenopathy from mRNA COVID-19 Vaccines
Teo, S. P. (2021) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.21.0057 · Cited by 3
Self-citation
Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine
Shaik, R. A., Ahmad, M. S., Alzahrani, M., Alzerwi, N. A. N., Alnemare, A. K., Reyzah, M., Albar, H. M., Alshagrawi, S. S., Elkhalifa, A. M. E., Alzahrani, R. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101689 · Cited by 3
Salivary immune responses after COVID-19 vaccination
Nguyen, K., Relja, B., Epperson, M., Park, S., Thornburg, N. J., Costantini, V., & Vinjé, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307936 · Cited by 2
Hemagglutinin-encoded mRNA vaccine confers efficient protection against H3N8 avian influenza virus in mice
Wu, J., Jiang, W., Guo, X., Li, J., Wang, S., Wan, Z., Xie, Q., Shao, H., Gao, W., Qin, A., et al. (2025) · Veterinary Microbiology · doi:10.1016/j.vetmic.2025.110847 · Cited by 2
Efficiency and immunogenicity of lipid nanoparticle-mediated cardiac mRNA delivery are lipid composition-dependent
Labonia, M. C. I., de Castilla, P. E. M., van der Kraak, P. H., Brans, M. A. D., Yang, Q., Lei, Z., de Jager, S. C. A., de Voogt, W. S., Schiffelers, R. M., Sluijter, J. P. G., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102939 · Cited by 3
Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy
Hamad, M., AlKhamach, D. M. H., Alsayadi, L. M., Sarhan, S. A., Saeed, B. Q., Sokóvić, M., Hadda, T. B., & Soliman, S. S. M. (2023) · Viral Immunology · doi:10.1089/vim.2022.0122 · Cited by 2
Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement
Hussain, W., Chaman, S., Koser, N., Aun, S. M., Bibi, Z., Pirzadi, A. N., Hussain, J. S., Zubaria, Z., Nabi, G., Ullah, M. W., et al. (2024) · Current Microbiology · doi:10.1007/s00284-024-03803-9 · Cited by 2
Case report: Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series
Taube, M., & Lesiņa, A. A. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1514428 · Cited by 2
A lyophilized anti-rabies mRNA-LNP vaccine induces early and robust immune responses from a single-dose subcutaneous administration
Wang, Y., Yu, T., Zhang, S., Li, N., Zhao, J., Mi, L., Cai, Y., Yao, N., Hu, R., & Miao, F. (2025) · Veterinary Microbiology · doi:10.1016/j.vetmic.2025.110612 · Cited by 2
Predictors of COVID-19 Vaccine Hesitancy and Its Relation to the Educational Background in Pakistan
Munir, M. D., Afzaal, H., Sajjid, M. H., Anwar, S., & Shabbir, M. H. (2021) · ASEAN Journal of Science and Engineering Education · doi:10.17509/ajsee.v1i2.40895 · Cited by 2
Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions DMD TNR
Klingel, H., Krüttgen, A., Imöhl, M., & Kleines, M. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.1.60 · Cited by 3
Development of mRNA nano-vaccines for COVID-19 prevention and its biochemical interactions with various disease conditions and age groups
Baig, M. M. F. A., Wong, L. Y., & Wu, H. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2288996 · Cited by 2
ppLM-CO:Pre-trained Protein Language Model for Codon OptimizationPreprint
Pathak, S., & Lin, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628267 · Cited by 3
Factors Affecting Parental Intent to Vaccinate Against COVID-19 in Kansas
Duncan, L. (2025) · Kansas Journal of Medicine · doi:10.17161/kjm.vol18.22762 · Cited by 1
Large‐Scale Screening of CD4 + T‐Cell Epitopes From SARS‐CoV‐2 Proteins and the Universal Detection of SARS‐CoV‐2 Specific T Cells for Northeast Asian Population
Zhao, Y., He, C., Peng, M., Li, M., Liu, X. K., Han, X., Fu, Q., Wu, Y., Yue, F., Yan, C., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70241 · Cited by 1
Exploring Potential Mechanisms for Epilepsy After mRNA COVID ‐19 Vaccination: An Extremely Rare Side‐Effect
Mutee, A. F., Shareef, A., Jyothi, S. R., Panigrahi, R., Abbot, V., Chauhan, A. S., Singh, S., Баходирович, А. Б., Sameer, H. N., Yaseen, A., et al. (2025) · Scandinavian Journal of Immunology · doi:10.1111/sji.70059 · Cited by 1
mRNA-based SARS-CoV-2 vaccines: intracellular processing and aggregation of the encoded spike protein as a mechanistic contributor to cardiac cellular stress
Schreckenberg, R., Woitasky, N., Itani, N., Czech, L., Windhorst, A., Juchem, M., Bär, C., Thum, T., Ferdinandy, P., & Schulz, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1635478 · Cited by 1
Emerging RNA Viruses: Epidemiology, Pathogenesis, and Challenges for Vaccine Development: Review
Obaid, Z. H., Abbas, A. S., Al-Shalah, L. A. M., & Ramadan, G. M. (2026) · Journal of Biomedicine and Biochemistry · doi:10.57238/jbb.2026.7432.1163 · Cited by 1
Lipid nanoparticles and endosomal escape: Characterizing the escape compartment and standardizing models
Bourguignon, T., Sharma, P., Hazan‐Halevy, I., & Peer, D. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103436 · Cited by 1
Nanoparticle-Mediated Antiviral Strategies for Pandemic Preparedness: Mechanisms, Applications, and Future Perspectives
Jamous, Y. F. (2026) · Pandemics · doi:10.3390/pandemics1020008 · Cited by 1
A branched ionizable lipid nanoparticle platform for versatile in vivo delivery of nucleic acids: Validation from mRNA to capped circular RNA
Kimura, S., Tsutsumi, S., Nakamura, N., Tsujihata, S., Fangjie, L., Nakashima, Y., Kita, S., Maenaka, K., Hashiya, F., Inagaki, M., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100555 · Cited by 1
Annular elastolytic giant cell granuloma after COVID-19 vaccination
Lora, V., Lamberti, A., Prete, M. D., Graceffa, D., & Cota, C. (2023) · Dermatology Reports · doi:10.4081/dr.2023.9811 · Cited by 1
Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report
Fujii, K., Fukuda, K., Kawakami, M., Mitani, A., Tanaka, G., & Kage, H. (2023) · Case Reports in Oncology · doi:10.1159/000533705 · Cited by 1
Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients
Stai, S., Fylaktou, A., Kasimatis, E., Xochelli, A., Λιούλιος, Γ., Nikolaidou, V., Παπαδοπούλου, Α., Myserlis, G., Iosifidou, A. M., Iosifidou, M. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11101583 · Cited by 1
Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
Fylaktou, A., Stai, S., Kasimatis, E., Xochelli, A., Nikolaidou, V., Παπαδοπούλου, Α., Myserlis, G., Λιούλιος, Γ., Asouchidou, D., Giannaki, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11111670 · Cited by 1
Separation of oligonucleotides by ion-exchange and ion-pair chromatography
Bartlett, M. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15369-3.00031-6 · Cited by 1
Navigating the horizon of mRNA vaccines: Tracing their evolution, ensuring safety, and unveiling therapeutic potential
Yap, E. C. T. (2023) · International e-Journal of Science Medicine & Education · doi:10.56026/imu.17.3.13 · Cited by 1
LEVERAGING THE SUCCESS OF MRNA LIPID NANOPARTICLE VACCINE IN COVID-19 TREATMENT: A NARRATIVE REVIEW ON ITS POTENTIAL APPLICATION IN MALARIA TREATMENT
Iheagwam, F. N., & Adedoyin, E. D. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i5.50885 · Cited by 1
Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines
Grimes, D. R. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126657 · Cited by 1
Research progress on lipid nanoparticle messenger RNA delivery system
He, S., & Liu, S. (2025) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2024-0709 · Cited by 1
RNA viruses: from RNA processing and interaction mechanisms to new prevention and control strategies
ZHANG, F., Tang, Y., Yu, J. I. A., & Zhou, Y. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0100 · Cited by 1
SARS Cov-2 Vaccines and Vaccination Strategies
House, N. N. C., & Sheeba, P. (2021) · Microbes and Infectious Diseases /Microbes and Infectious Diseases · doi:10.21608/mid.2021.207742
Application of Synthetic Biology in SARS-CoV-2 Vaccine Development
Zhang, Y. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/3/20220261 · Cited by 1
Development and application of an uncapped mRNA platformPreprint
Zheng, X., Liu, B., Ni, P., Cai, L., Shi, X., Ke, Z., Zhang, S., Hu, B., Yang, B., Xu, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.05.494796 · Cited by 1
Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA VaccinationPreprint
Devaux, C. A., Colson, P., Raoult, D., & Camoin‐Jau, L. (2023) · Preprints.org · doi:10.20944/preprints202311.1883.v1
Real-World Effectiveness of a Third Dose of mRNA-1273 versus BNT162b2 on Inpatient and Medically Attended COVID-19 among Immunocompromised Adults in the United StatesPreprint
Sun, T., Li, L., Mues, K. E., Georgieva, M. V., Kirk, B., Mansi, J. A., de Velde, N. V., & Beck, E. C. (2024) · medRxiv · doi:10.1101/2024.01.30.24302015 · Cited by 1
Living Organ Donor Hesitancy about COVID-19 Vaccines: A New Kind of “Source Control Issue”
Jorgenson, M. R. (2021) · Kidney360 · doi:10.34067/kid.0003402021
New age in vaccinology: the impact of the COVID-19 pandemic on third-generation vaccine development
Ramos, E. L. P., Vedova-Costa, J. M. D., Pacce, V. D., Ferreira, G. N., Guzmán, Y. C. M., Boschero, R. A., Hospinal-Santiani, M., & Thomaz‐Soccol, V. (2021) · Biotechnology Research and Innovation · doi:10.4322/biori.202103
The prevention and treatment of Covid-19 and related development during pandemic
Wang, C., Lee, Y., Yeh, C., & Chan, C. (2021) · Journal of Food Bioactives · doi:10.31665/jfb.2021.16290
Safety and efficacy of COVID-19 Vaccines in special populations
Alattas, S. G., Ibrahim, I. M., Ali, A. S., Barakat, J., Shaker, A. A., Momen, T. N., Mohamed, A. S., Alfadil, A., & Alharbi, A. E. (2022) · Journal of Contemporary Medical Sciences · doi:10.22317/jcms.v8i2.1197
COVID-19 Vaccination in India
Ghosh, S. K., Adhikari, A., Mukhopadhyay, A., Bose, S., & Sharma, K. (2022) · Springer eBooks · doi:10.1007/978-981-16-9336-6_12
Awareness, Practice, and Acceptance of COVID-19 Vaccination among Medical Students from Mansoura University, Egypt: A Cross-sectional Survey
Katamesh, B. E., Katamesh, M. E., Abdalrhman, W. A., Eldeeb, R. M., Hareera, N. M., Raslan, A. E., Alabd, A. A., & Neel, E. A. A. (2022) · Epidemiology and Health System Journal · doi:10.34172/ijer.2022.23
Mechanism of Action and Impact of the New Coronavirus Vaccine
Zhao, H. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v54i.9719
Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 Messenger Ribonucleic Acid Vaccines in Infected Individuals: A Systematic Review
Roslan, M., Nisfu, F. R. M., Arzmi, M. H., Wahab, R. A., & Zainuddin, N. (2023) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2023.30.4.2 · Cited by 1
Molecular evaluation of SARS-CoV-2 in post-vaccinated patients of Malakand division Khyber PakhtunkhwaPreprint
abbas, W., Amir, S., & Rafiullah, R. (2023) · Research Square · doi:10.21203/rs.3.rs-3542406/v1
Evaluation of the clinical use and impact of Miao medicine's anti influenza mask on IgA in human serum and SIgA in nasal mucosa
Wang, M., Xiao, Y., Wang, Z., Gan, L., Zhou, X., & Zeng, Y. (2024) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v22i12.17
THE SCIENCE OF HOPE: A COMPREHENSIVE REVIEW OF COVID-19 VACCINE PROGRESS
Srivastava, A., Chaturvedi, V., Wal, P., Srivastava, P., Wal, A., & Yadav, A. (2022) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v29i04.4383
Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged ≥12 yearsPreprint
Kawamoto, A., Hashida, M., Ishida, K., Furihata, K., Ota, A., Takahashi, K., Sakakibara, S., Nakano, T., & Takeshita, F. (2024) · medRxiv · doi:10.1101/2024.11.14.24317321
journey of the avian influenza virus H5N1 through 30 years of evolutionary events, geographical locations, and animal species
Prüß, B. M. (2025) · International Journal of Health Sciences · doi:10.53730/ijhs.v9n1.15502
Enhancing funding strategies for medical research and technology innovation in China: insights from international proof of concept initiatives
Yao, G., Wang, F., Zhu, Y., & Sun, R. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-1002
Physical and Chemical Properties of RNA Therapeutics
Byrn, S. R., Zografi, G., & Chen, X. (. (2025) · Wiley eBooks · doi:10.1002/9781394254484.ch21
Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study
Kawamoto, A., Hashida, M., Ishida, K., Furihata, K., Ota, A., Takahashi, K., Sakakibara, S., Nakano, T., & Takeshita, F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004499
SARS‐CoV‐2 Antibody Levels and Infections in Multiple Vaccinated Employees Over Time
Sander, I., Kespohl, S., Beine, A., Belting, K., Bünger, J., Weidhaas, S., Hosbach, I., Eisenhawer, C., Gleichenhagen, J., Göcke, P., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70628
Exploring the impact of nucleotide length on lipid nanoparticle structure and properties
Hammel, M., Fan, Y., Kim, L. J., Zang, N., Xiao, B., Caliò, A., Yen, C., & Hura, G. L. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126944
Nanotechnology-based vaccine development for COVID-19
Nayyar, A., Kanyal, B., Yadav, A., Tomar, R. S., Shree, P., Singh, C. K., Narang, P. K., & Sodhi, K. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00016-6
Future Trends in NSCLC and Care
Shahraki, R. A. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-2096-0.ch013
An overview of the mRNA applications and their therapeutic functions in clinical development
Ramakrishnaiah, T. N., Srikar, K. S., Deb, A., Ahmed, K. S., Chandraghatgi, R. R., Sarin, Y., Roopini, K., & Rajashekara, S. (2026) · Next research. · doi:10.1016/j.nexres.2026.101413
Structural Design of T-Cell Epitope-Based mRNA Vaccine Constructs Determines the Quality of T-Cell Immunity and Protective Efficacy Against SARS-CoV-2 in Mice
Gushchin, V. A., Siniavin, A. E., Pochtovyi, A. A., Dzharullaeva, A. S., Щербинин, Д. Н., Ungur, A. S., Ильдарович, Т. А., Shuliakova, I. V., Kleymenov, D. A., Mazunina, E. P., et al. (2026) · Vaccines · doi:10.3390/vaccines14030281
Modern Materials for Non-Viral Delivery Systems in Gene Therapy
Radnaeva, A. V., Slobodkina, E. A., Tkachuk, V. A., & Makarevich, P. I. (2026) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00287
A chimeric trivalent Echovirus vaccine designed by loop substitution elicits cross-neutralizing immunity against serotypes 11, 18, and 30
Jiang, S., Cui, J., Sun, T., Li, J., Li, H., Chen, T., Wu, J., Zheng, Z., Xia, J., Wu, C., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00457-26
Analysis of mRNA purity by pseudo-absorbance and conventional absorbance sedimentation velocity analytical ultracentrifugationPreprint
Zhang, Y., Yu, Q., Zhao, Q., Shi, Z., Wang, Z., Duan, X., Zhao, Y., Zhang, Y., Ye, M., Wang, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9206353/v1
Emerging the Potential of mRNA Technology in Covid-19 Vaccine Manufacturing
Taher, M., Rosdi, M. I. A. M., Nur, M. S. I. M. N., Zainuri, Q. A., Shokri, N. S. I. M. N., Pazli, N. H. M., Susanti, D., Zaini, E., & Khotib, J. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_16
A bivalent mRNA–LNP vaccine confers broad-spectrum protection against both homologous and heterologous H5/H7 highly pathogenic avian influenza viruses in SPF chickens
Wei, D., Pan, Y., Zhang, X., Quan, Y., Feng, S., Huang, M., Sun, L., Yang, Y., Zhou, J. M., Han, X., et al. (2026) · Veterinary Research · doi:10.1186/s13567-026-01790-2
Smart Design: Integrating Artificial Intelligence and Gene Editing for Advanced mRNA Therapeutics
Shi, H., Liu, S., Dai, D., Jiang, S., Tian, T., Niu, Z., Xiang, Z., Zou, C., Liu, F., Tang, X., et al. (2026) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70062
Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents
Olagunju, O. J., Oyebanji, O. A., Keresztesy, D., Wilk, D. J., Dickerson, E., Wallace, T., Holland, L., Payne, M., See, E., Li, C. J., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2705661
Mannosylated Spleen-Targeted Lipid Nanoparticles Enable Enhanced mRNA Delivery to Antigen-Presenting Cells
Zhang, S., Li, Y., Teymur, A. A., Yang, B., Majd, S., Mohan, C., & Wu, T. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00494
The COVID-19 RNA vaccine SpikevaxTM transfects human umbilical endothelial cells and induces Spike protein production, inflammation and leukocyte adhesionPreprint
Cosentino, M., Ferrari, M., Schiavone, N., Rasini, E., Luini, A., Legnaro, M., Federico, M., Marino, F., & Frajese, G. V. (2026) · Research Square · doi:10.21203/rs.3.rs-11220160/v1
Size and morphology optimization-driven in vivo targeting of nanomedicines: Mechanisms and characterization techniques
Wu, J., Song, L., Zhu, C., Liao, Y., Zhang, H., Zhang, W., & Zou, Z. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103032
Multi-omics integration reveals vaccine-specific molecular signatures and temporal dynamics of COVID-19 immune responses
Klein, A. H., Beale, D., Nguyen, T. V., Liu, J., van Vuren, P. J., Singanallur, N. B., Lee, C., Boomer, A. C., Juno, J. A., Kent, S. J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1815543

Authors: Teo, S. P.
Affiliations: Raja Isteri Pengiran Anak Saleha Hospital (BN)
Corresponding author: Teo, Shyh Poh
ORCID: Teo, Shyh Poh
Venue: Journal of Pharmacy Practice
Publisher: SAGE Publications
Published: 2021-04-12
Volume: 35
Issue: 6
Pages: 947-951
ISSN: 0897-1900 (ISSN-L)
1531-1937
DOI: 10.1177/08971900211009650
OpenAlex: W3154719862
Cited by: 191
References: 26
Citations by year: 2026: 24 · 2025: 42 · 2024: 35 · 2023: 39 · 2022: 37 · 2021: 14
FWCI: 3.65
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Pharmacy Practice (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: COVID-19 mRNA vaccine, BNT162b2, mRNA-1273, SARS-CoV-2, vaccine development, vaccine efficacy, immunogenicity, vaccine safety, emergency use authorization, vaccine thermostability, underrepresented groups
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Humans, RNA, Viral, United States, Viral Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks